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The epidemic-like rise in the prevalence of obesity con-
stitutes an undoubted and serious global health problem.
Importantly, hypertension and diabetes are frequently asso-
ciated with obesity and, together, constitute a signiﬁcant
burden in terms of patients’ morbidity and escalating health
care costs. When considered in isolation, obesity, hyperten-
sion, and diabetes are all associated with increased risk of
the development of cardiovascular and renal complications;
however, the coexistence of this triumvirate generates a sub-
stantial elevation in disease risk. The driving forces linking
obesity, hypertension, and diabetes remain to be clariﬁed
due, in part, to the complex and multifactorial nature of
the conditions that involve combinations of environmental,
genetic,lifestyle,andbehaviouralconfounders.Additionally,
it is recognized that neuroendocrine mechanisms, including
insulin resistance, sympathetic nervous activation, and stim-
ulationoftherenin-angiotensin-aldosterone system (RAAS),
are also involved [1–4].
This special issue on hypertension and type 2 diabetes
related to obesity includes several epidemiological studies
focusing on the prevalence of metabolic syndrome, type
2 diabetes, and hypertension. New data emanating from
Peru, Ethiopia, Sudan, Egypt, and Nepal documents the
prevalence of cardiometabolic disease in these countries as
being similar to that reported in westernized countries such
as the USA, Canada, Australia, and European countries as
well as Japan [5, 6]. Importantly, an emerging body of
data, such as that presented by Professor C. Brufani et al.,
highlights the importance of obesity in children. They
reported the contribution of birth weight to central fat
depot and insulin sensitivity in metabolic syndrome in obese
Italian children. The challenge will be in designing and
implementing eﬀective strategies to arrest and reverse this
pattern.
The strong linkage between hypertension and type 2
diabetes was reviewed by Professor E. Dean which provides
insight into the mechanisms involved. Dr. S. Horita et al.
reviewed the contribution of the kidneys, especially renal
sodium transport, to the development of insulin resis-
tance and hypertension in obesity. Diabetic patients and
obese individuals frequently present with diﬀerent circadian
patterns of blood pressure compared to nondiabetic or
nonobese subjects. A nondipping pattern is very common in
obese hypertensive patients. In diabetic patients, ambulatory
blood pressure monitoring provides a more robust measure
in predicting future cardiovascular events than clinic blood
pressure. Dr. C. Anigbogu et al. provided evidence that in
rats the circadian rhythm of blood pressure and heart rate
changes with progression of diabetes. Professor K. Eguchi
reviewed recent epidemiological studies in diabetes and
obesity using ambulatory blood pressure monitoring. Taken
together, these observations demonstrate the importance of
ambulatory blood pressure monitoring.
The ﬁrst line of therapy for the treatment of type 2
diabetes and obesity-related hypertension is weight loss with
lifestylemodiﬁcationssuchasdietandexercise.Nonpharma-
cological treatments were outlined by Dr. J. Pappachan et al.
Another article by S. Guy et al. indicated that video gaming
provided some beneﬁt in initiating lifestyle modiﬁcations
that aided in weight loss. Patients with diabetes and
hypertension frequently present with atherogenic diseases
and dyslipidemia. Dr. E. Morales-Villegas and colleagues2 International Journal of Hypertension
provided a review indicating that statins are very eﬀective
in treating dyslipidemia and reducing overall cardiovascular
risk.
This special issue covered a wide range of materials
with a focus on type 2 diabetes and hypertension. Articles
included epidemiology, physiology, and treatments. In sum-
mary, this issue demonstrated that (i) abdominal obesity
is related to the high prevalence of hypertension and type
2 diabetes regardless of ethnicity, (ii) insulin resistance is
a major mechanism linking the onset and development
of hypertension and type 2 diabetes, and (iii) weight loss
with diet and exercise is an important aspect in treating
hypertension in type 2 diabetes and aids in increasing the
eﬃcacy of antihypertensive medications. Further investiga-
tions on mechanisms and genetics are needed in order to
develop appropriate and eﬀective therapeutic regimens in
order to prevent and limit obesity-related illnesses such as
hypertension and type 2 diabetes. Early intervention is vital,
given emerging evidence of end-organ dysfunction in young
overweight or obese individuals [7, 8].
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